Literature DB >> 3125168

Characterization of the sulfonylurea receptor on beta cell membranes.

K L Gaines1, S Hamilton, A E Boyd.   

Abstract

Specific, high affinity sulfonylurea receptors were characterized on membranes of an insulin-secreting hamster beta cell line (HIT cells). Saturable binding of the sulfonylurea, [3H]glyburide, was linear up to 0.8 mg/ml membrane protein. Scatchard analysis of equilibrium binding data at room temperature indicated the presence of a single class of saturable, high affinity binding sites with a Kd of 0.76 +/- 0.04 nM and a Bmax of 1.09 +/- 0.13 pmol/mg protein, n = 9. The insulin secretory potency of glyburide, glipizide, tolbutamide, tolazamide, and carboxytolbutamide was compared to the ability of these ligands to displace [3H]glyburide from the sulfonylurea receptor. Tolbutamide, tolazamide, and glipizide demonstrated reasonable agreement with ED50 values of 15 microM, 3 microM, and 30 nM and Ki values of 25.3 microM, 7.2 microM, and 45 nM, respectively. The inactive tolbutamide metabolite, carboxytolbutamide, at the highest concentration tested, only partially displaced [3H]glyburide from the receptor and was a very poor secretagogue. At 37 degrees C the affinity of [3H]glyburide binding, Kd = 2.0 nM, was similar to the ED50 of 5.5 nM when the free glyburide concentrations were corrected for binding of the drug to albumin. These studies suggest that sulfonylureas initiate their biologic effect through a high affinity, specific interaction with sulfonylurea receptors on the beta cell membrane.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3125168

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  22 in total

1.  Ca(2+)-activated K+ channels from an insulin-secreting cell line incorporated into planar lipid bilayers.

Authors:  Y Oosawa; S J Ashcroft; F M Ashcroft
Journal:  Diabetologia       Date:  1992-07       Impact factor: 10.122

2.  The beta-cell glibenclamide receptor is an ADP-binding protein.

Authors:  I Niki; J L Nicks; S J Ashcroft
Journal:  Biochem J       Date:  1990-06-15       Impact factor: 3.857

3.  BRL 34915 (cromakalim) activates ATP-sensitive K+ current in cardiac muscle.

Authors:  M C Sanguinetti; A L Scott; G J Zingaro; P K Siegl
Journal:  Proc Natl Acad Sci U S A       Date:  1988-11       Impact factor: 11.205

4.  Intracellular localization and molecular heterogeneity of the sulphonylurea receptor in insulin-secreting cells.

Authors:  S E Ozanne; P C Guest; J C Hutton; C N Hales
Journal:  Diabetologia       Date:  1995-03       Impact factor: 10.122

5.  Location of the sulphonylurea receptor at the cytoplasmic face of the beta-cell membrane.

Authors:  M Schwanstecher; C Schwanstecher; C Dickel; F Chudziak; A Moshiri; U Panten
Journal:  Br J Pharmacol       Date:  1994-11       Impact factor: 8.739

6.  Structural requirements of sulphonylureas and analogues for interaction with sulphonylurea receptor subtypes.

Authors:  M Meyer; F Chudziak; C Schwanstecher; M Schwanstecher; U Panten
Journal:  Br J Pharmacol       Date:  1999-09       Impact factor: 8.739

7.  ATP-sensitive K-channels in HIT T15 beta-cells studied by patch-clamp methods, 86Rb efflux and glibenclamide binding.

Authors:  I Niki; R P Kelly; S J Ashcroft; F M Ashcroft
Journal:  Pflugers Arch       Date:  1989-10       Impact factor: 3.657

Review 8.  Management of antidiabetic medications in overdose.

Authors:  H A Spiller
Journal:  Drug Saf       Date:  1998-11       Impact factor: 5.606

9.  Effects of glibenclamide on cytosolic calcium concentrations and on contraction of the rabbit aorta.

Authors:  K Yoshitake; K Hirano; H Kanaide
Journal:  Br J Pharmacol       Date:  1991-01       Impact factor: 8.739

10.  Effect of MgATP on pinacidil-induced displacement of glibenclamide from the sulphonylurea receptor in a pancreatic beta-cell line and rat cerebral cortex.

Authors:  M Schwanstecher; C Brandt; S Behrends; U Schaupp; U Panten
Journal:  Br J Pharmacol       Date:  1992-06       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.